Table 3.
Carotenoids and cancer risk.
β-Carotene | α-Carotene | β-Cryptoxanthin | Lycopene | Lutein + zeaxanthin | |
---|---|---|---|---|---|
High intake | Ovarian (postmenopausal) ↓ [116] | ||||
High intake | Bladder ↓ [117] | Bladder ↓ [117] | Bladder ↓ [117] | Bladder ↔ [117] | Bladder ↔ [117] |
Supplement | Bladder ↑ [118] | ||||
High intake | Breast (ER+, ER+/PR+) ↑ [95] | Breast ↓ [95] | Breast ↓ [95] | Breast (ER−/PR+ or ER−/PR−) ↓ [95] | Breast (ER−/PR+ or ER−/PR−) ↓ [95] |
(ER−/PR+ or ER−/PR−) ↓ [95] | |||||
Supplement | Gut (colorectal) ≈↑ [119] | ||||
High intake | Gut (esophageal) ↓ [120] | Gut (esophageal) ↓ [120] | Gut (esophageal) ↓ [120] | Gut (esophageal) ↓ [120] | Gut (esophageal) ↓ [120] |
High intake | Gut (gastric) ↓ [121, 122] | Gut (gastric) ↓ [121, 122] | Gut (gastric) ↔ [121, 123] | Gut (gastric) (lutein) ↔ [121] | |
Supplement | Gut (liver) ↔ [124] | ||||
High intake | Gut (pancreatic) ↓ [125] | Gut (pancreatic) ↔ [125] | Gut (pancreatic) ↓ [125] | Gut (pancreatic) ≈↓ [125] | Gut (pancreatic) ↔ [125] |
Supplement | Gut gastric ≈↑ [126] | ||||
Supplement | Gut intestinal ↑ [126] | ||||
High intake | Hodgkin lymphoma ↓ [127] | Hodgkin lymphoma ↓ [127] | Hodgkin lymphoma ↔ [127] | Hodgkin lymphoma ↔ [127] | Hodgkin lymphoma ↓ [127] |
High intake | Lung ↓ [128] | ||||
Supplement | Lung ↑ [7, 129] | ||||
High intake | melanoma ≈↓ [130] | ||||
Supplement | Oral ↔ [131] | ||||
High intake | Oral ↓ [132] | Oral ↓ [132] | Oral ↓ [132] | Oral ↓ [132] | |
High intake | Prostate ↔ [133] | Prostate ↓ [133] | Prostate ↓ [112, 133] | ||
Supplement | Prostate ↔ [134] |
≈ ns. increase or decrease; ↓: decrease; ↑: increase; ↔: no change; ER: estrogen receptor; PR: progesterone receptor.